drugset / Trial / NCT00382239

A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes

NCT00382239

Phase 2 Completed 153 enrolled AstraZeneca Eli Lilly and Company · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will examine the response of several doses of LY2148568 (exenatide) and assess the effect on glucose control and safety and tolerability in Japanese patients with type 2 diabetes.

Timeline

Start
2006-09
Primary completion
2007-05
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 2.5 ug Subcutaneous
Subject Exenatide Peptide 5 ug Subcutaneous
Subject Exenatide Peptide 10 ug Subcutaneous